|
1
|
Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the
classification of the acute leukaemias French-American-British
(FAB) Co-operative Group. Br J Haematol. 33:451–458. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Döhner H, Estey EH, Amadori S, Appelbaum
FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson
RA, et al: Diagnosis and management of acute myeloid leukemia in
adults: Recommendations from an international expert panel, on
behalf of the European LeukemiaNet. Blood. 115:453–474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dohner H, Weisdorf DJ and Bloomfield CD:
Acute Myeloid Leukemia. N Engl J Med. 373:1136–1152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferrara F and Del Vecchio L: Acute myeloid
leukemia with t(8;21)/AML1/ETO: A distinct biological and clinical
entity. Haematologica. 87:306–319. 2002.PubMed/NCBI
|
|
5
|
Isobe M, Emanuel BS, Givol D, Oren M and
Croce CM: Localization of gene for human p53 tumour antigen to band
17p13. Nature. 320:84–85. 1986. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Levine AJ: p53, the cellular gatekeeper
for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gualberto A, Aldape K, Kozakiewicz K and
Tlsty TD: An oncogenic form of p53 confers a dominant,
gain-of-function phenotype that disrupts spindle checkpoint
control. Proc Natl Acad Sci USA. 95:5166–5171. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carson DA and Lois A: Cancer progression
and p53. Lancet. 346:1009–1011. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Amundson SA, Myers TG and Fornace AJ Jr:
Roles for p53 in growth arrest and apoptosis: Putting on the brakes
after genotoxic stress. Oncogene. 17:3287–3299. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kirsch DG and Kastan MB: Tumor-suppressor
p53: Implications for tumor development and prognosis. J Clin
Oncol. 16:3158–3168. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Toshinori O and Akira N: Role of p53 in
cell death and human cancers. Cancers. 3:994–1013. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Petitjean A, Mathe E, Kato S, Ishioka C,
Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53
functional properties on TP53 mutation patterns and tumor
phenotype: Lessons from recent developments in the IARC TP53
database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Orazi A, Cattoretti G, Heerema NA, Sozzi
G, John K and Neiman RS: Frequent p53 overexpression in therapy
related myelodysplastic syndromes and acute myeloid leukemias: An
immunohistochemical study of bone marrow biopsies. Mod Pathol.
6:5211993.PubMed/NCBI
|
|
14
|
Cleven AH, Nardi V, Ok CY, Goswami M, Dal
Cin P, Zheng Z, Iafrate AJ, Abdul Hamid MA, Wang SA and Hasserjian
RP: High p53 protein expression in therapy-related myeloid
neoplasms is associated with adverse karyotype and poor outcome.
Mod Pathol. 28:552–563. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lane DP, Cheok CF and Lain S: p53-based
cancer therapy. Cold Spring Harb Perspect Biol. 2:a0012222010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Di Agostino S, Cortese G, Monti O,
Dell'Orso S, Sacchi A, Eisenstein M, Citro G, Strano S and Blandino
G: The disruption of the protein complex mutantp53/p73 increases
selectively the response of tumor cells to anticancer drugs. Cell
Cycle. 7:3440–3447. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang S, Zhou L, Hong B, van den Heuvel
AP, Prabhu VV, Warfel NA, Kline CL, Dicker DT, Kopelovich L and
El-Deiry WS: Small-Molecule NSC59984 restores p53 pathway signaling
and antitumor effects against colorectal cancer via p73 activation
and degradation of mutant p53. Cancer Res. 75:3842–3852. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chiao JW, Wu H, Ramaswamy G, Conaway CC,
Chung FL, Wang L and Liu D: Ingestion of an isothiocyanate
metabolite from cruciferous vegetables inhibits growth of human
prostate cancer cell xenografts by apoptosis and cell cycle arrest.
Carcinogenesis. 25:1403–1408. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu L, Liu D, Ma X, Beklemishev A, Seiter
K, Ahmed T and Chiao JW: The phenylhexyl isothiocyanate induces
apoptosis and inhibits leukemia cell growth in vivo. Oncol Rep.
16:1363–1367. 2006.PubMed/NCBI
|
|
20
|
Ma X, Fang Y, Beklemisheva A, Dai W, Feng
J, Ahmed T, Liu D and Chiao JW: Phenylhexyl isothiocyanate inhibits
histone deacetylases and remodels chromatins to induce growth
arrest in human leukemia cells. Int J Oncol. 28:1287–1293.
2006.PubMed/NCBI
|
|
21
|
Zhuang Z, Huang Y, Ma X, et al: Histone
Methylation and Acetylation Modulated by PHI in Prostate Cancer PC3
Cell Line Acta Medicinae Universitatis Scientiae Et Technologiae
Huazhong 06. 2012.
|
|
22
|
Lai YD, Ma XD, Huang YQ, Xu XN, Wang XZ,
Chiao DJ and Liu D: Modulation of histone acetylation and induction
of apoptosis in SMMC-7721 cells by phenylhexyl isothiocyanate.
Zhonghua Zhong Liu Za Zhi. 32:8042010.(In Chinese). PubMed/NCBI
|
|
23
|
Jiang S, Ma X, Huang Y, Xu Y, Zheng R and
Chiao JW: Reactivating aberrantly hypermethylated p15 gene in
leukemic T cells by a phenylhexyl isothiocyanate mediated
inter-active mechanism on DNA and chromatin. J Hematol Oncol.
3:482010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yong Z, Ma X, Huang Y, Hong L and Chiao J:
Effect of phenylhexyl isothiocyanate on aberrant histone H3
methylation in primary human acute leukemia. J Hematol Oncol.
5:362012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Del PG, Venditti A, Del Principe MI,
Maurillo L, Buccisano F, Tamburini A, Cox MC, Franchi A, Bruno A,
Mazzone C, et al: Amount of spontaneous apoptosis detected by
Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).
Blood. 101:2125–2131. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Redza-Dutordoir M and Averill-Bates DA:
Activation of apoptosis signalling pathways by reactive oxygen
species. Biochim Biophys Acta. 1863:2977–2992. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kischkel FC, Lawrence DA, Tinel A, LeBlanc
H, Virmani A, Schow P, Gazdar A, Blenis J, Arnott D and Ashkenazi
A: Death receptor recruitment of endogenous caspase-10 and
apoptosis initiation in the absence of caspase-8. J Biol Chem.
276:466392001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boulares AH, Yakovlev AG, Ivanova V,
Stoica BA, Wang G, Iyer S and Smulson M: Role of poly(ADP-ribose)
polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP
mutant increases rates of apoptosis in transfected cells. J Biol
Chem. 274:22932–22940. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shaulsky G, Ben-Ze'Ev A and Rotter V:
Subcellular distribution of the p53 protein during the cell cycle
of Balb/c 3T3 cells. Oncogene. 5:1707–1711. 1990.PubMed/NCBI
|
|
30
|
Liao N, Sun L, Chen J, Zhong J, Zhang Y
and Zhang R: A novel polysaccharide conjugate from Bullacta exarata
induces G1-Phase arrest and apoptosis in human hepatocellular
carcinoma HepG2 cells. Molecules. 22:3842017. View Article : Google Scholar
|
|
31
|
Parrales A and Iwakuma T: Targeting
oncogenic mutant p53 for Cancer Therapy. Front Oncol. 5:2882015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aggarwal M, Saxena R, Sinclair E, Fu Y,
Jacobs A, Dyba M, Wang X, Cruz I, Berry D, Kallakury B, et al:
Reactivation of mutant p53 by a dietary-related compound phenethyl
isothiocyanate inhibits tumor growth. Cell Death Differ.
23:1615–1627. 2016. View Article : Google Scholar : PubMed/NCBI
|
